Delcath Systems (NASDAQ:DCTH – Get Free Report) and Sharps Technology (NASDAQ:STSS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.
Profitability
This table compares Delcath Systems and Sharps Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Delcath Systems | -2,308.86% | -563.60% | -111.13% |
| Sharps Technology | N/A | -103.10% | -76.46% |
Risk and Volatility
Delcath Systems has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Delcath Systems | $2.07 million | 55.13 | -$47.68 million | ($2.97) | -1.51 |
| Sharps Technology | N/A | N/A | -$9.84 million | N/A | N/A |
Sharps Technology has lower revenue, but higher earnings than Delcath Systems.
Insider & Institutional Ownership
61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 17.2% of Sharps Technology shares are held by institutional investors. 21.1% of Delcath Systems shares are held by company insiders. Comparatively, 14.1% of Sharps Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Delcath Systems and Sharps Technology, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Delcath Systems | 0 | 0 | 4 | 0 | 3.00 |
| Sharps Technology | 0 | 0 | 1 | 0 | 3.00 |
Delcath Systems currently has a consensus price target of $18.50, suggesting a potential upside of 313.41%. Given Delcath Systems’ higher possible upside, analysts plainly believe Delcath Systems is more favorable than Sharps Technology.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
About Sharps Technology
Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
